1.65Open1.40Pre Close18 Volume11 Open Interest22.50Strike Price2.80KTurnover140.44%IV11.79%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry1.55Extrinsic Value100Contract SizeAmericanOptions Type-0.3676Delta0.0562Gamma11.88Leverage Ratio-0.0860Theta-0.0040Rho-4.37Eff Leverage0.0180Vega
Vera Therapeutics Stock Discussion
Major Milestone: 431 Patients Enrolled in Vera's Groundbreaking IgAN Treatment Trial
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025
📊⚡️📊
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
No comment yet